期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

RNAi对人乳腺癌MCF-7细胞E2F1、TS基因表达的抑制作用 被引量：1

Inhibition effect of RNAi to E2F1 and TS genes expression in human breast cancer MCF-7 cell
下载PDF
导出
摘要 目的观察RNA干扰(RNAi)技术对乳腺癌细胞MCF-7中E2F1、胸苷酸合成酶(TS)基因表达的靶向抑制作用。方法设计合成并构建重组质粒pSIREN-E2F1,将重组质粒转染MCF-7细胞。筛选稳定转染的单克隆细胞扩大培养,应用RT-PCR方法检测各组细胞E2F1、TS mRNA表达情况。结果转染组E2F1、TS基因表达均受到抑制。结论RNAi技术特异、高效抑制靶基因E2F1及TS表达。 Objective To deect the inhibition of RNAi techinque to the expression of E2Flgene in breast cancer cell line MCF-7 and investigate the expression of TS gene. Method Recombinant plasmid pSIREN-E2F1 was constructed and transfeeted into human breast cancer cell line MCF-7. And then selected the stable transfected cells scaling up cuhure. The expression of E2F1 and TS gene were detected by RT-PCR. Result The expression of E2F1mRNA and TSmRNA were suppressed in pSIREN-E2F1 transfected cells. Conclusion RNAi can effectively suppress the expression of E2F1 and TS gene in human breast cancer cell and provide an effective anti-cancer gene therapy.
作者 黄慧敏 李惠翔 张红 姜国忠 赵阿红
机构地区 河源市人民医院 郑州大学第一附属医院
出处 《山东医药》 CAS 北大核心 2008年第43期8-9,共2页 Shandong Medical Journal
关键词 E2F1基因 胸苷酸合成酶基因 RNA干扰 肿瘤抑制 E2F1 gene thymidylate synthase gene RNA inhibition tumor suppressor
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1Sellers WR, Kaelin WG. Role of the retinoblastoma protein in the pathogenesis of human cancer[ J]. Clin Oneol, 1997, 15 ( 11 ) : 3301-4412.
  • 2Shi YZ, Shao CL, luma F,et al. E2FI: a proliferative marker of breast neoplasia [ J ]. Epidemiol Biomarkers Prey, 2000, 9 (4) : 395-401.
  • 3Li Q, Boyer C, Lee J, et al. A novel approach to thymidylate synthase as a target for cancer chemotherapy[ J ]. Mol Phar, 2001,59 (3) :446-452.
  • 4黄慧敏,张红,李惠翔,姜国忠,高冬玲,王秀利.表达E2F1小干扰RNA的逆转录病毒载体的构建[J].实用诊断与治疗杂志,2005,19(3):177-179. 被引量：5
  • 5Han S, Park K, Bae BN, et al. E2F1 expression is related with the poor survival of lymph node-positive breast patients treated with fluorouracil, doxorubicin and cyclophosphamidereast[J]. Breast Cancer Res B Treat, 2003,82(1) :11-16.
  • 6Izqnierdo M. Short interfering RNAs as a tool for cancer gene therapy[J]. Cancer Gene Ther, 2005, 12(3) :217-227.
  • 7Chio J, Lira H, Nam DK, et al. Expression of thymidylate synthase in gastric cancer patients treated with 5-fluomuracil and doxorubicinbased adjuvant chemotherapy after curative resection[ J]. Br J Cancer ,2001,84(2) :186-192.

二级参考文献18

  • 1Hannon G J, Conklin D S. RNA interference by short hairpin RNAs expressed in vertebrate cells[J]. Methods Mol Biol,2004,257 (1) :255.
  • 2Xia H B, Mao Q W, Paulson H L, et al. Si-RNA mediated gene silencing in vitro and in vivo[J]. Nat Biotechnol, 2002,20: 1006.
  • 3Holen T, Amarzguioui M, Wiiger M T, et al. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue faetor[J]. Nucleic Acids Res, 2002,30(8) : 1757.
  • 4Brummelkamp T R, Bernards R. A system for stable expression of short interfering RNAs in mammalia cells[J]. Science,2002,296:550.
  • 5Shuey D, McCAIIus D E, Giodano T. RNAi.. gene silencing therapeutic intervention[J]. DDT, 2002,7(20) : 1040.
  • 6Miyagishi M, Taira K. RNAi expression vectors in mammalian cells[J]. Methods Mol Biol, 2004,252 (1) : 483.
  • 7Sui G, Soohoo C, Affarel B, et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells[J].Proc Natl Acad Sci USA, 2002,99(8):5515.
  • 8Miyagishi M, Taira K. U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells [J]. Nat Biotechnol, 2002, 20(5) :497.
  • 9Sellers W R, Kaelin W G Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer [J]. J Clin Oncol, 1997,15 :3301.
  • 10Suzuki T, Yasui W, Yokozaki H, et al. Expression of the E2F family in human gastrointestinal carcinomas [J]. Int J Cancer,1999,81:535.

共引文献4

同被引文献15

  • 1Jemal A, Bray F, Center M M, et al. Global cancer statistics [ J]. CA: A Cancer Journal for Clinicians, 2011,61(2) : 69-90.
  • 2Muhsin M, Gricks C, Kirkpatrick P. Pemetrexed diso- dium[ J ]. Nat Rev Drug Discov, 2004, 3 (10): 825 -826.
  • 3Rouquette I, Mazieres J. A brief overview of a lung canc- er biomarker: thymidylate synthase [ J ]. Revue des mala- dies respiratoires, 2011,28 (6) :773-777.
  • 4Ozasa H, Oguri T, Uemura T, et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer[J]. Cancer science, 2010, 101 ( 1 ) :161-166.
  • 5Roe O D, Szulkin A, Anderssen E, et al. Molecular re- sistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma [ J ]. PloS one, 2012, 7(8) : e40521.
  • 6Takezawa K, Okamoto I, Okamoto W, et al. Thymidy- late synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer [ J ]. British J cancer, 2011, 104(10) : 1594-1601.
  • 7Mairinger F, Vollbrecht C, Halhwedl I, et al. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-trea- ted patients suffering from malignant pleural mesothelio- ma[J]. J Thorac Oncol,2013, 8(5) : 644-653.
  • 8Zucali P A, Giovannetti E, Destro A, et al. Thymidy- late synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin [ J ]. Clini- cal Cancer Research, 2011, 17(8) : 2581-2590.
  • 9Bepler G, Sommers K E, Cantor A, et al. Clinical effi- cacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer [J]. J Thorac Oncol, 2008, 3 (10): 1112-1118.
  • 10Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination ox- aliplatin and fluorouracil chemotherapy [ J ]. J Clini On- col, 2001,19 (23) :4298-4304.

引证文献1

山东医药
2008年 第43期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部